Antibiotic Resistance in Streptococcus pneumoniae after Azithromycin Distribution for Trachoma

Journal of Tropical Medicine

Volumn 2015, Issue , 2015, Pages

  Ho, Derek K H ^a   Sawicki, Christian ^b   Grassly, Nicholas ^c  

^a WILLIAM HARVEY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF TORONTO   (Canada)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIUM ISOLATE; CHLAMYDIA TRACHOMATIS; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS PNEUMONIAE; TRACHOMA;

EID: 84946944132     PISSN: 16879686     EISSN: 16879694     Source Type: Journal    
DOI: 10.1155/2015/917370     Document Type: Review

References (35)

1. S. P. Mariotti, D. Pascolini, and J. Rose-Nussbaumer, "Trachoma: global magnitude of a preventable cause of blindness," British Journal of Ophthalmology, vol. 93, no. 5, pp. 563-568, 2009.
2. WHO, "Trachoma," 2014, http://www. who. int/gho/neglected diseases/trachoma/en/.
3. I. M. Blake, M. J. Burton, R. L. Bailey et al. , "Estimating household and community transmission of ocular Chlamydia trachomatis," PLoS Neglected Tropical Diseases, vol. 3, no. 3, article e401, 2009.
4. N. C. Grassly, M. E. Ward, S. Ferris, D. C. Mabey, and R. L. Bailey, "The natural history of trachoma infection and disease in a Gambian cohort with frequent follow-up," PLoS Neglected Tropical Diseases, vol. 2, no. 12, article e341, 2008.
5. P. M. Emerson, M. Burton, A. W. Solomon, R. Bailey, and D. Mabey, "The SAFE strategy for trachoma control: using operational research for policy, planning and implementation," Bulletin of theWorldHealthOrganization, vol. 84,no. 8, pp. 613-619, 2006.
6. WHO, "Blinding trachoma: progress towards global elimination by 2020," 2006, http://www. who. int/mediacentre/news/notes/2006/np09/en/.
7. WHO,Weekly Epidemiological Record,WHO, Geneva, Switzerland, 2012.
8. G. G. Zhanel, K. D. Wolter, C. Calciu et al. , "Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae: analysis of Phase 3 clinical trial data," Journal of Antimicrobial Chemotherapy, vol. 69, no. 10, pp. 2835-2840, 2014.
9. S. K. West, J. Moncada, B. Munoz et al. , "Is there evidence for resistance of ocular Chlamydia trachomatis to azithromycin after mass treatment for trachoma control?" Journal of Infectious Diseases, vol. 210, no. 1, pp. 65-71, 2014.
10. F. Baquero, J. Mart?nez-Beltrán, and E. Loza, "Areviewof antibiotic resistance patterns of Streptococcus pneumoniae in Europe," Journal of Antimicrobial Chemotherapy, vol. 28, supplement C, pp. 31-38, 1991.
11. S. Malhotra-Kumar,C. Lammens, S. Coenen, K. VanHerck, and H. Goossens, "Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebocontrolled study," The Lancet, vol. 369, no. 9560, pp. 482-490, 2007.
12. T. C. Collaboration, Trachoma-Categorised Reviews, The Cochrane Library, 2014, http://www. thecochranelibrary. com/details/browseReviews/577825/Trachoma. html.
13. Y. Uo, "NIHR Centre for Reviews and Dissemination-CRD Database 2014," http://www. crd. york. ac. uk/CRDWeb/.
14. Cochrane, "TheCochrane Collaboration's tool for assessing risk of bias[16/11/14] . http://ohg. cochrane. org/sites/ohg. cochrane. org/files/uploads/Risk%20of%20bias%20assessment%20tool. pdf.
15. J. P. T. Higgins and S. G. Thompson, "Quantifying heterogeneity in ameta-analysis," Statistics inMedicine, vol. 21,no. 11,pp. 1539-1558, 2002.
16. A. J. Leach, T. M. Shelby-James, M. Mayo et al. , "A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae," Clinical InfectiousDiseases, vol. 24,no. 3, pp. 356-362, 1997.
17. A. Fry, H. C. Jha, T. M. Lietman et al. , "Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal," Clinical Infectious Diseases, vol. 35, no. 4, pp. 395-402, 2002.
18. S. L. Batt, B. M. Charalambous, A. W. Solomon et al. , "Impact of azithromycin administration for trachoma control on the carriage of antibiotic-resistant Streptococcus pneumoniae," Antimicrobial Agents and Chemotherapy, vol. 47, no. 9, pp. 2765-2769, 2003.
19. B. D. Gaynor, K. A. Holbrook, J. P. Whitcher et al. , "Community treatment with azithromycin for trachoma is not associated with antibiotic resistance in Streptococcus pneumoniae at 1 year," British Journal of Ophthalmology, vol. 87, no. 2, pp. 147-148, 2003.
20. B. D. Gaynor, J. D. Chidambaram, V. Cevallos et al. , "Topical ocular antibiotics induce bacterial resistance at extraocular sites," British Journal of Ophthalmology, vol. 89, no. 9, pp. 1097-1099, 2005.
21. S. Haug, T. Lakew, G. Habtemariam et al. , "The decline of pneumococcal resistance after cessation of mass antibiotic distributions for trachoma," Clinical Infectious Diseases, vol. 51, no. 5, pp. 571-574, 2010.
22. A. H. Skalet, V. Cevallos, B. Ayele et al. , "Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster-randomized clinical trial," PLoS Medicine, vol. 7, no. 12, Article IDe1000377, 2010.
23. C. L. Coles, K. Mabula, J. C. Seidman et al. , "Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistant Streptococcus pneumoniae carriage in young children 6 months after treatment," Clinical Infectious Diseases, vol. 56, no. 11, pp. 1519-1526, 2013.
24. NCfCLS, "Performance standards for antimicrobial susceptibility testing: approved standard," Document M100-S9, NCCLS,Wayne, Pa, USA, 1999.
25. CALSI, "Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement," CLSIDocument M44-53, CALSI,Wayne, Pa, USA, 2009.
26. S. O. Holm, H. C. Jha, R. C. Bhatta et al. , "Comparison of two azithromycin distribution strategies for controlling trachoma in Nepal," Bulletin of theWorld Health Organization, vol. 79, no. 3, pp. 194-200, 2001.
27. H. M. Lode, "Managing community-acquired pneumonia: a European perspective," Respiratory Medicine, vol. 101, no. 9, pp. 1864-1873, 2007.
28. M. Woodhead, F. Blasi, S. Ewig et al. , "Guidelines for the management of adult lower respiratory tract infections-full version," ClinicalMicrobiology and Infection, vol. 17, supplement 6, pp. E1-E59, 2011.
29. L. A. Mandell, R. G. Wunderink, A. Anzueto et al. , "Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults," Clinical Infectious Diseases, vol. 44, supplement 2, pp. S27-S72, 2007.
30. W. S. Lim, S. V. Baudouin, R. C. George et al. , "BTS guidelines for the management of community acquired pneumonia in adults: update 2009," Thorax, vol. 64, supplement 3, pp. iii1-iii55, 2009.
31. H. Goossens, M. Ferech, R. V. Stichele, and M. Elseviers, "Outpatient antibiotic use in Europe and association with resistance: a cross-national database study,"The Lancet, vol. 365, no. 9459, pp. 579-587, 2005.
32. T. Gebre, B. Ayele, M. Zerihun et al. , "Comparison of annual versus twice-yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster-randomised trial," The Lancet, vol. 379, no. 9811, pp. 143-151, 2012.
33. M. C. Maher,W. Alemayehu, T. Lakew et al. , "The fitness cost of antibiotic resistance in streptococcus pneumoniae: insight from the field," PLoS ONE, vol. 7, no. 1,Article ID e29407, 2012.
34. L. Van Heirstraeten, S. Coenen, C. Lammens, N. Hens, H. Goossens, and S. Malhotra-Kumar, "Antimicrobial drug use and macrolide-resistant Streptococcus pyogenes, Belgium," Emerging Infectious Diseases, vol. 18, no. 9, pp. 1515-1518, 2012.
35. M. Woolhouse and J. Farrar, "Policy: an intergovernmental panel on antimicrobial resistance," Nature, vol. 509, no. 7502, pp. 555-557, 2014.